Dr. Satya (Nanu) Das to Be Featured Guest for CCF’s Luncheon with the Experts
Satya (Nanu) Das, MD, MSCI, medical oncologist and hematologist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, will be the featured guest for Facebook Live Luncheon with the Experts on Thursday, January 27, 2022 from 12 noon to 1 pm, Eastern…READ MORE
Dr. Thomas Hope to Be Featured Guest for CCF’s Luncheon with the Experts
Thomas Hope, MD, Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, and Chief of Nuclear Medicine at the San Francisco VA Medical Center, will be the featured guest for …READ MORE
Dr. Sugandha Dureja to be Featured Guest for CCF’s Luncheon with the Experts
Sugandha Dureja, MD, FEBNM, nuclear medicine specialist, will be the featured guest for Facebook Live Luncheon with the Experts on Thursday, August 12, 2021 from 12 noon to 1 pm, Eastern Time.
Dr. Dureja is among the first Indian specialists with international…READ MORE
Dr. Nancy Sharma to be Featured Guest for Luncheon with the Experts
Nancy Sharma, MD, medical oncologist and hematologist at Swedish Cancer Institute in Issaquah, Washington, will be the featured guest for CCF’s Facebook Live Luncheon with the Experts on Thursday, May 20 from 12 noon to 1 pm, Eastern Time.
Growing up …READ MORE
Dr. Lale Kostakoglu-Shields to Be Featured Guest for Luncheon with the Experts
Lale Kostakoglu-Shields, MD, MPH, a nuclear medicine expert, will be the featured guest for CCF’s Luncheon with the Experts on Thursday, April 15, 2021 from 12 noon to 1 pm, Eastern Time. Dr. Kostakoglu-Shields is a professor of radiology and medical…READ MORE
Peptide Receptor Radionuclide Therapy, PRRT: Updates and Locations
Since we shared the news of the FDA’s January 26, 2018 approval of peptide receptor radionuclide therapy, PRRT, with Lutathera (lutetium Lu 177 dotatate), more information has become available for the neuroendocrine tumor community, including updates…READ MORE
PRRT – FDA Approves Lutathera®, What’s Next?
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is this
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors …READ MORE
One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers
The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017. Additionally, an Expanded…READ MORE
News and Notes for the Carcinoid and Neuroendocrine Tumor Community, April 2016
Rare Neuroendocrine Skin Cancer Treated by Immunotherapy
Merkel cell carcinoma, a rare neuroendocrine virus-linked skin cancer, has been added to the list of cancers that can be treated by immunotherapy. Scientists who led the clinical study of the…READ MORE